82 results about "Therapeutic group" patented technology

The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.

The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising a Burkholderia antigen) that generate an effective immune response (e.g., against a bacterial species of the genus Burkholderia) in a subject administered the immunogenic composition. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications.

A method for treating tissue through a branched luminal network of a patient is provided. A pathway to a point of interest in branched luminal network of a patient is generated. An extended working channel is advanced transorally into the branched luminal network and along the pathway to the point of interest. The extended working channel may be positioned in a substantially fixed orientation at the point interest. A tool is advanced though the extended working channel to the point of interest. Tissue at the point of interest is treated.

A focused-ultrasound or other procedure for treating a target within a tissue region can be planned iteratively by creating a treatment plan specifying a treatment location pattern and stimuli applied thereto, simulating the treatment, computationally predicting an effect of the simulated treatment, comparing the predicted effect against one or more treatment constraints (such as efficacy and/or safety thresholds), and, if a constraint is violated, repeating the simulation for an adjusted treatment plan.

Systems and methods of localizing or delivery cells, biologics and/or drugs to a specific target area to treat pelvic health disorders are provided. A treatment composition including cells, biologics and/or drugs are associated with magnetic particulates, and the positioning of these materials is facilitated through use of a magnetic field-generating device that is configured to be placed on or into a pelvic anatomical structure. Certain embodiments directed to the treatment of ED in male patients can include a cell based therapy system.

The invention discloses a single-chain antibody of human source anti-alexin C3d molecules. A light chain and a heavy chain of the antibody have a unique CDR region; excellent antigen binding activityis realized; the affinity constant reaches 1.22*10<-7> mol/L. Biological distribution experiments prove that the anti-C3d single-chain antibody provided by the invention can be highly gathered in thearthritis positions after entering a mouse model with rheumatoid arthritis; the arthritis serious degree of the three ScFv treatment groups is obviously lower than that of a PBS group; the healing degree has the obvious dose dependency relationship; the result shows that the excellent anti-adhesion/ anti-inflammatory targeted inhibition effects are achieved. In the treatment process on MRL/lpr mice with lupus erythematosus, the anti-C3d single-chain antibody provided by the invention can obviously improve the survival rate of the mice; the symptoms of proteinuria, glomerular score, interstitial inflammation, vasculitis and crescent/necrosis and the like in the treatment group are obviously relieved. The result shows that the anti C3d single-chain antibody provided by the invention has excellent application prospects in the preparation of medicine for treating autoimmune diseases.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. In particular, provided herein are optimized systems and methods that provide targeted, efficacious histotripsy in a variety of different regions and under a variety of different conditions without causing undesired tissue damage to intervening/non-target tissues or structures.

Disclosed are linear discrete PEG constructs, which can be created and produced in a precise and reproducible way. Key to being able to do these things, where x in the discrete PEG_x can vary from about 2 to about 64, is that the processes used to make each linear portion is controlled to give essentially one oligomer/one compound. Having a variable length linear discrete PEG construct that is (a) primarily an linear discrete PEG construct with diagnostic or therapeutic groups attached along a chain of attachment cores, which is attached to a preferential locator; (b) is an m-discrete PEG as the terminal construct on the linear portion, and “hidden”; (c or linear discrete PEG with a terminus group that can be either negatively or positively charged, or neutral; and any of the discrete PEG portions can be designed to be cleaved after entering the cell.

The invention discloses a fusion protein of a single-chain antibody of a human anti-complement C3d molecule and a complement inhibitor CD59. The antibody has excellent antigen binding activity. Biological distribution experiments prove that the fusion protein provided by the invention can be rapidly and highly aggregated at an arthritis part after entering a rheumatoid arthritis mouse model, and has an excellent anti-adhesion/anti-inflammation targeting inhibition effect. In treatment of MRL/lpr lupus erythematosus mice, the fusion protein provided by the invention can obviously improve the survival rate of the mice, and symptoms of proteinuria, glomerular score, interstitial inflammation, vasculitis, crescent/necrosis and the like of a treatment group are obviously improved, so that the fusion protein provided by the invention has an excellent application prospect in preparation of medicaments for treating autoimmune diseases.

Devices, systems, and methods for therapeutically treating tissue. The devices and methods are suitable for minimally invasive surgery or open surgical procedures. More particularly, methods and devices described herein permit accessing and/or treating areas of tissue with a therapeutic device.

A self-exploration assembly includes a base and a plurality of petals each shaped so that when the plurality of petals are coupled to the base in a first orientation, the plurality of petals together resemble an onion, and, when the plurality of petals are coupled to the base in a second orientation, the plurality of petals resemble a flower.

The invention discloses a single-chain antibody of a human anti-complement C3d molecule, and a fusion protein of the single-chain antibody and a complement inhibitor DAF. The antibody has excellent antigen binding activity. Biological distribution experiments prove that the fusion protein provided by the invention can be rapidly and highly aggregated at an arthritis part after entering a rheumatoid arthritis mouse model, and has an excellent anti-adhesion/anti-inflammation targeting inhibition effect. In treatment of MRL/lpr lupus erythematosus mice, the fusion protein provided by the invention can obviously improve the survival rate of the mice, and symptoms of proteinuria, glomerular score, interstitial inflammation, vasculitis, crescent/necrosis and the like of a treatment group are obviously improved, so that the fusion protein provided by the invention has an excellent application prospect in preparation of medicaments for treating autoimmune diseases.

The invention belongs to the field of preparation of composite micelle entrapped drugs, and particularly relates to a composite nano micelle for multi-mode treatment of nasopharyngeal carcinoma and apreparation method and application thereof. The composite nano micelle for multi-mode treatment of nasopharyngeal carcinoma is characterized by comprising Bangladesh rose red and an amphiphilic peptide nano micelle for encapsulating the Bangladesh rose red. According to the invention, the amphiphilic peptide of C18-GRRRRRRRRGDScontaining a tripeptide sequence of arginine, glycine and aspartic is self-assembled into a nano micelle, and the inside of the nano micelle is wrapped with Bangladesh red; the results show that the a combined therapy group has obvious inhibitory effect on CNE-2Z tumor during intravenous injection. During intratumor injection, a photodynamic therapy group (RBNs+Laser) with laser added alone, a sonodynamic therapy group (RBNs+US) with ultrasound added alone and a combination therapy group (RBNs+Laser+US) all have a significant inhibitory effect on tumor growth.

The invention discloses a method for performing interceptive treatment on osteoarthritis of knee joints through dental pulp stem cells (DPSCs). The method comprises the following steps: injecting CFA(Complete Freund's Adjuvant) and MIA (Sodium Iodoacetate) through an articular cavity and performing induction for one week to obtain a rat model of the osteoarthritis of the knee joints; performing intervention and treatment on different groups of rats after one week, wherein a treatment group adopts interceptive treatment in a way of DPSCs cell suspension liquid articular cavity orthotopic injection or intravenous injection; taking materials after treatment for 4 weeks and analyzing a treatment effect, and evaluating the treatment effect of DPSCs on the osteoarthritis of the knee joints. According to the method disclosed by the invention, an experimental result proves that the DPSCs has a treatment effect on bone osteoarthritis induced by combination of CFA and MIA; after treatment for 4weeks, through DPSCs systematic or local injection, a knee joint bone structure induced by the combination of CFA and MIA can be recovered, and exudates of the articular cavity are reduced. Through the DPSCs systematic or local injection, a transparent cartilage arrangement structure and cell forms can be recovered.

The invention specifically discloses an application of MSC for inhibiting virus replication, especially an application of MSC for inhibiting virus replication of a viral infection patient, and relatesto the technical field of biomedical engineering. According to the invention, a prepared MSC preparation is added into an MSC treatment group to carry out combined treatment on the viral infection patient, so that ribosomal gene expression of the patient can be recovered to the level of health personnel after the MSC treatment group is healed, and virus replication can be effectively inhibited after the MSC treatment group is healed.

The present disclosure provides methods of conducting and analyzing mouse clinical trials. In one embodiment, the method comprises the steps of receiving a dataset of tumor volumes measured in a mouse clinical trial, determining tumor growth curve of the treatment group and tumor growth curve of the control group; determining area under curve (AUC) of the treatment group and AUC of the control group; and evaluating efficacy of the drug based on an AUC ratio between the AUC of the treatment group and the AUC of the control group, wherein the mouse clinical trial comprises the steps of: obtaining a tumor sample derived from a patient; grafting the tumor sample to a treatment group comprising m mice and a control group comprising n mice, wherein m and n are integers; treating the treatment group with a drug; treating the control group with a vehicle; and measuring tumor volume of the treatment group and tumor volume of the control group at a plurality of days.

The invention particularly discloses an application of MSC to regulation and control of gene expression of effector CD8+ T cells, in particular to application of MSC to regulation and control of geneexpression of effector CD8+ T cells of viral infection patients, and relates to the technical field of biomedical engineering. The prepared MSC preparation is added into an MSC treatment group to carry out combined treatment on a patient with viral infection, so that the condition of effector CD8+ T cell gene expression of the patient after the patient is healed through the MSC treatment group iseffectively improved; due to the fact that proliferation of effector CD8+ T cells can be promoted through gene expression of the effector CD8+ T cells, a patient treated through the MSC treatment group has higher anti-inflammatory capacity, and meanwhile a higher chemotactic effect is achieved.

This invention relates to a therapeutic composition comprising i) at least two immune checkpoint inhibitors, ii) at least one drug selected from a cytokine a cytotoxic or cytostatic chemotherapeutic drug, and combinations thereof, and iii) a cancer vaccine prepared from tumor or cancer cells, or derivatives thereof, that have been prepared through an ex vivo treatment that creates necrotic and/or necroptotic cancer cells while minimizing destruction of cancer antigens. This invention also relates to a method of treating a tumor or a cancer in a patient comprising administering to a patient in need thereof the therapeutic composition in an amount effective to treat the tumor or cancer.

A device and a system for treatment of tissue by direct application thereto of therapeutic substances in the form of a stream of therapeutic droplets carried in a high velocity gas. The high velocitygas is produced by accelerating a flow of gas through at least one gas discharge nozzle. At least one flow of therapeutic substance is introduced into the high velocity gas through at least one liquiddischarge nozzle, thereby fragmenting the at least one flow of therapeutic liquid into a stream of therapeutic droplets. The stream is accelerated to a velocity similar to the velocity of the gas discharge flow. The accelerated therapeutic droplet stream is then applied to a tissue for therapeutic treatment. The device and the system contain a gas stream shield generator that provides a shield which prevents rebounding and dispersing droplets produced after impinging on the tissue from travelling in the direction of a user.

The invention discloses double-track motion focusing radiotherapy equipment. The double-track motion focusing radiotherapy equipment comprises a fixed rack and a rotary rack, and the fixed rack is provided with an annular sleeve structural part; the rotary rack is provided with a circular ring type structural part and a supporting structural part, the circular ring type structural part is connected with the supporting structural part, the circular ring type structural part is located on the inner side of the annular sleeve structural part and connected with the annular sleeve structural part through a bearing, and the circular ring type structural part and the annular sleeve structural part are connected with a rotating driving device; the rotating driving device drives the circular ring type structural part to rotate along the annular sleeve structural part; and a treatment assembly and an imaging component are installed on the supporting structural part, and a driving mechanism is installed on the supporting structural part and can drive the treatment assembly to slide. According to the device, the imaging component and the treatment assembly are integrated, so that the accuracy of image guiding and target spot positioning is improved, the radiotherapy time is shortened, damage to normal tissues and visceral organ cells of a patient is reduced through a double-track focusing method, and a treatment scheme can be more optimized.

The invention relates to a data processing method based on clinical test data, belongs to the technical field of clinical test evaluation, and solves the problems that the deviation caused by crowd heterogeneity is not fully eliminated and the data is not fully utilized to improve the inference precision in the prior art. The method comprises the following steps: acquiring data samples of a treatment group and a control group in a clinical test; determining a sample survival estimation model under a potential treatment result based on the data samples of the treatment group and the control group; acquiring a covariable related to a treatment effect in the sample survival estimation model, and calculating according to the sample survival estimation model to obtain potential result estimation of a survival individual under a treatment scheme and the probability that the individual is in a survival state; according to the above-mentioned potential outcome estimates of the surviving individuals under the treatment plan and the probability of the individuals being in a survival state, determining the confidence interval of the average causal effect SACE of the survival group. The confidence interval of the SACE obtained by the method can be used for judging whether a clinical test is effective or not, and the inference conclusion is accurate.